NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee A meeting minutes

**Minutes:** Confirmed

**Date:** Tuesday 7 March 2023

**Location:** Via Zoom

## Attendees

Committee members present

1. Dr Radha Todd (Chair) Present for all items
2. Dr James Fotheringham (Vice-chair) Present for all items
3. Richard Ballerand Present for all items
4. Dr Andrew Champion Present for all items
5. Dr Justin Daniels Present for all items
6. Ana Duarte Present for all items
7. Dr Steve Edwards Items 1 to 4.3.2
8. Dr Fiona MacPherson Smith Present for all items
9. Professor G.J. Melendez-Torres Items 5 to 5.2.2
10. Dr Pratheeban Nambyiah Present for all items
11. Dominic Pivonka Items 5 to 5.2.2
12. Alan Thomas Present for all items
13. Min Ven Teo Items 1 to 4.3.2
14. Jacqueline Tomlinson Present for all items
15. Stella O’Brien Present for all items
16. Malcolm Oswald Items 1 to 5.2.2

NICE staff (key players) present

Janet Robertson, Associate Director Items 1 to 4.3.2

Richard Diaz, Associate Director Items 6 to 6.2.2

Jeremy Powell, Project Manager Items 1 to 4.3.2

Thomas Feist, Project Manager Items 5 to 5.2.2

Daniel Davies, Project Manager Items 6 to 6.2.2

Mary Hughes, Health Technology Assessment Adviser Items 1 to 4.3.2

Joanna Richardson, Health Technology Assessment Adviser Items 5 to 5.2.2

Victoria Kelly, Health Technology Assessment Adviser Items 6 to 6.2.2

Marcela Haasova, Health Technology Assessment Analyst Items 1 to 4.3.2

Alexandra Sampson, Health Technology Assessment Analyst Items 5 to 5.2.2

Harsimran Sarpal, Health Technology Assessment Analyst Items 6 to 6.2.2

Adam Storrow, Business Analyst, Resource Impact Present for all items

Ruth Melville, Senior Medical Editor Items 1 to 4.3.2

Anna Sparshatt, Senior Editor Items 5 to 5.2.2

Ella Fitzpatrick, Public Involvement Adviser Items 1 to 4.1.3

Emma Gordon, Coordinator, Corporate Office Items 1 to 4.1.3 & 5 to 5.1.3

Carl Jackson, Assistant Project Manager, Committee Operations Team Present for all items

Leah Murphy, Administrator, Technology Appraisals Items 1 to 5.2.2

Marcia Miller, Administrator, Technology Appraisals Items 5 to 5.2.2

NICE staff (observers) present

Janine Wigmore, Public Involvement Adviser Items 1 to 5.2.2

Sarah Wilkes, Technical Analyst, Managed Access Items 5 to 5.2.2

External assessment group representatives present

Professor G.J. Melendez-Torres, Peninsula Technology Assessment Group (Pen-TAG), Items 1 to 4.2.1 & 6 to 6.1.3

Jaesh Naik, Peninsula Technology Assessment Group (Pen-TAG), Items 1 to 4.2.1

Tracey Jhitta, BMG Group Items 5 to 5.1.3

Vicky Wakefield, BMG Group Items 5 to 5.1.3

Clinical, Patient & NHS England experts present

Amy Deptford, Policy Manager, patient expert nominated by Crohn’s & Colitis UK Items 1 to 4.1.3

Kamila Kingstone, Policy Adviser, patient expert nominated by Crohn’s & Colitis UK Items 1 to 4.1.3

Dr Mark Saaman, Consultant Gastroenterologist, clinical expert nominated by AbbVie Ltd Items 1 to 4.1.3

Professor Peter Clark, Cancer Drug Fund Clinical Lead, NHS England Items 1 to 4.3.2

## Minutes

### Introduction to the meeting

* 1. The chair welcomed members of the committee and other attendees present to the meeting.
	2. The chair noted apologies from Peter Baker-Gulliver, Becky Pennington, Dr Craig Buckley, Hugo Pedder, Dr Louis Choo, Mohit Sharma, and Mohamad Farhat.

### News and announcements

* 1. None.

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Tuesday 7 February 2023.

### Appraisal of Risankizumab for previously treated moderately to severely active Crohn's disease [ID3986]

* 1. Part 1 – Open session
		1. The vice chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Abbvie Ltd.
		2. The vice chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Prior to the meeting, Dominic Pivonka declared direct financial interests as his employer (Abbvie Ltd) is the company sponsor and a possible comparator company. Dominic Pivonka’s declaration prevented him from participating in discussions on this appraisal.
* Prior to the meeting, Dr Fiona MacPherson-Smith declared a personal interest as her husband has IBD managed by the NHS and is currently treated with ustekinamab, which has induced remission. It was agreed that her declaration would not prevent Dr Fiona MacPherson-Smith from participating in discussions on this appraisal.
* Dr Mark Saaman declared direct financial interests as he has received advisory fees from Janssen, Takeda, Sandoz, Samsung, Bioepis, Galapagos, and Abbvie Ltd. Dr Mark Saamon has also received lectern fees from Bristol Myers-Squibb, Janssen, Takeda, Merck Sharp & Dohme, Falk, Abbvie Ltd, and Galapagos. It was agreed that his declarations would not prevent Dr Mark Saamon from providing expert advice to the committee.
* No further interests were declared for this appraisal.
	+ 1. The Vice Chair hair led a discussion of the evidence presented to the committee. This information was presented to the committee by the vice chair.
	1. Part 2a – Closed session (members of the public, clinical and patient experts, and company representatives were asked to leave the meeting).
		1. The committee discussed confidential information submitted for this item.
	2. Part 2b – Closed session (external assessment group representatives were asked to leave the meeting)
		1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10884>.

### Appraisal of Olaparib for maintenance treatment of recurrent, platinum-sensitive ovarian, fallopian tube and peritoneal cancer that has responded to platinum-based chemotherapy (managed access review of TA620) [ID3788]

* 1. Part 1 – Open session
		1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from AstraZeneca.
		2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Prior to the meeting, Dr Steve Edwards stated that he is a member of the EAG for this appraisal. As a direct conflict Steve did not participate in the discussions on this appraisal.
* No further interests were declared for this appraisal.
	+ 1. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by the chair.
	1. Part 2 – Closed session (company representatives, external assessment group representatives and members of the public were asked to leave the meeting)
		1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10712>.

### Appraisal of Tezepelumab for treating severe asthma [ID3910]

* 1. Part 2a – Closed session (this discussion was held in a private part 2 session only, without the public, company representatives, or the experts in attendance.
		1. The chair welcomed the external assessment group representatives.
		2. The chair asked all committee members, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Prior to the meeting, Dominic Pivonka declared a direct financial interest as his employer (AbbVie) has a medicine in a different therapy area (atopic dermatitis) which is a competitor to one of the comparators (dupilumab) in this appraisal. Dominic Pivonka’s declaration prevented him from participating in discussions on this appraisal.
* No further interests were declared for this appraisal.
	+ 1. The committee discussed confidential information submitted for this item.
	1. Part 2b – Closed session (external assessment group representatives were asked to leave the meeting)
		1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10796>.

### Date of the next meeting

The next meeting of the Technology Appraisal Committee A will be held on Tuesday 4 April 2023 and will start promptly at 10.00am.